Hélène E. Aschmann

TL;DR: The authors in this article evaluated the prevalence of impaired health status and physical and mental health symptoms among individuals at least six months after SARS-CoV-2 infection, and to characterize their healthcare utilization.

TL;DR: All statins showed statistically significant risk reduction of CVD and all‐cause mortality in primary prevention populations while increasing the risk for some harm risks, however, the benefit‐harm profile differed by statin type.

TL;DR: In this article, the authors identify the expected risk above which statins provide net benefit, with baseline risk, frequencies of and preferences for statin benefits and harms, and competing risk for non-CVD death taken into account.

TL;DR: This study provides much needed empirical evidence on preferences that help clinical guidelines consider for weighing the benefit and harm outcomes when recommending for or against statins for primary prevention of cardiovascular disease.

TL;DR: The authors in this paper assessed the prevalence of impaired health status and physical and mental health symptoms among individuals at least six months after SARS-CoV-2 infection, and to characterise their healthcare utilisation.